Growth Metrics

Standard Biotools (LAB) Consolidated Net Income (2016 - 2026)

Standard Biotools has reported Consolidated Net Income over the past 16 years, most recently at $5.4 million for Q4 2025.

  • Quarterly Consolidated Net Income rose 178.01% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$39.4 million through Dec 2025, up 38.71% year-over-year, with the annual reading at -$16.1 million for FY2025, 66.48% up from the prior year.
  • Consolidated Net Income was $5.4 million for Q4 2025 at Standard Biotools, up from -$3.0 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $20.7 million in Q4 2023 and troughed at -$76.3 million in Q1 2022.
  • The 5-year median for Consolidated Net Income is -$17.1 million (2021), against an average of -$20.1 million.
  • Year-over-year, Consolidated Net Income crashed 305.33% in 2022 and then surged 185.57% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at -$13.9 million in 2021, then crashed by 74.3% to -$24.2 million in 2022, then surged by 185.57% to $20.7 million in 2023, then plummeted by 133.36% to -$6.9 million in 2024, then soared by 178.01% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Consolidated Net Income are $5.4 million (Q4 2025), -$3.0 million (Q3 2025), and -$15.8 million (Q2 2025).